PAULO FRANCISCO RAMOS MARGARIDO

(Fonte: Lattes)
Índice h a partir de 2011
6
Lattes
Projetos de Pesquisa
Unidades Organizacionais
Departamento de Obstetrícia e Ginecologia, Faculdade de Medicina - Docente
SCGINEC-62, Hospital Universitário
LIM/58 - Laboratório de Ginecologia Estrutural e Molecular, Hospital das Clínicas, Faculdade de Medicina

Filtros

Limpar filtros

Configurações

Revista / Livro: Clinical and Experimental Obstetrics & Gynecology ×

Resultados de Busca

Agora exibindo 1 - 1 de 1
  • article 6 Citação(ões) na Scopus
    Transdermal estrogen therapy effects on fibrinogen levels in women with a past history of venous thromboembolism: a pilot study
    (2011) MARGARIDO, P. F. R.; BAGNOLI, V. R.; FONSECA, A. Maggio da; MACIEL, G. A. R.; SOARES JR., J. M.; D'AMICO, E. A.; BARACAT, E. C.
    Objective: To evaluate thromboelastographic parameters and fibrinogen levels in women treated with transdermal 17 beta estradiol. Methods: 29 menopausal women with a history of venous thromboembolic disease were included. Nine patients composed the treatment (HT) group and 20 the control group. Coagulation was assessed by thromboelastography in samples of whole blood and platelet-poor plasma (PPP). The following thromboelastographic variables were measured: time for initial coagulation (R), blood clotting speed (K and the a angle), clot tensile strength (MA and G), global index of coagulation (Cl) and fibrinolysis (LY30) and fibrinogen levels. Results: There were no differences in the other parameters comparing both groups. Fibrinogen levels showed a 13.77 +/- 19.94% reduction in the HT group and a 5.51 +/- 8.09% increase in the control group after 6 months. Conclusions: Our data suggested that transdermal estrogen may not increase blood coagulability, but that it reduces fibrinogen levels in FIT women.